Bank of America’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-36,592
| Closed | -$25.5K | – | 8124 |
|
|
2023
Q1 | $25.5K | Buy |
36,592
+18,321
| +100% | +$16.9K | ﹤0.01% | 6687 |
|
|
2022
Q4 | $16.4K | Sell |
18,271
-224
| -1% | -$649 | ﹤0.01% | 6794 |
|
|
2022
Q3 | $111K | Buy |
+18,495
| New | +$105K | ﹤0.01% | 6297 |
|
|
2022
Q1 | – | Sell |
-4,297
| Closed | -$19K | – | 9000 |
|
|
2021
Q4 | $19K | Buy |
+4,297
| New | +$21.8K | ﹤0.01% | 7542 |
|
|
2021
Q3 | – | Sell |
-1,903
| Closed | -$13K | – | 8536 |
|
|
2021
Q2 | $13K | Sell |
1,903
-5,932
| -76% | -$32K | ﹤0.01% | 7254 |
|
|
2021
Q1 | $46K | Buy |
7,835
+3,843
| +96% | +$23.3K | ﹤0.01% | 6665 |
|
|
2020
Q4 | $18K | Buy |
3,992
+908
| +29% | +$3.91K | ﹤0.01% | 6616 |
|
|
2020
Q3 | $12K | Sell |
3,084
-3,125
| -50% | -$62.8K | ﹤0.01% | 6419 |
|
|
2020
Q2 | $179K | Buy |
6,209
+2,530
| +69% | +$58.6K | ﹤0.01% | 5324 |
|
|
2020
Q1 | $79K | Buy |
3,679
+2,978
| +425% | +$67.6K | ﹤0.01% | 5650 |
|
|
2019
Q4 | $14K | Buy |
+701
| New | +$9.96K | ﹤0.01% | 6590 |
|
Bank of America's STSA Position: Q2 2023 in Review
Bank of America sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 36,592 shares — an estimated $25.5K sold.
Bank of America first reported a position in STSA in Q4 2019 and held it in 11 quarters. The position peaked at $179K in Q2 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.
- Bank of America reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Bank of America sold 36,592 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $25.5K.
- Bank of America first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
- Bank of America's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $179K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.
Based on Bank of America's 13F filing for Q2 2023, filed 14 Aug 2023.